featured
Efficacy and Safety of Bulevirtide Monotherapy Through 96 Weeks Among Patients With Chronic Hepatitis Delta Virus
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Hepatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial
J. Hepatol. 2024 Oct 01;81(4)621-629, H Wedemeyer, S Aleman, M Brunetto, A Blank, P Andreone, P Bogomolov, V Chulanov, N Mamonova, N Geyvandova, V Morozov, O Sagalova, T Stepanova, A Berger, S Ciesek, D Manuilov, RC Mercier, BL Da, GM Chee, M Li, JF Flaherty, AH Lau, A Osinusi, J Schulze Zur Wiesch, M Cornberg, S Zeuzem, P LamperticoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.